11:42 AM EDT, 07/08/2024 (MT Newswires) -- (Updates with share price movement in the headline and first paragraph.)

Pulse Biosciences ( PLSE ) shares were up more than 25% in recent trading Monday after the US Food and Drug Administration granted Breakthrough Device Designation to its nsPFA cardiac surgery system for the ablation of cardiac tissue to treat atrial fibrillation.

The company said it plans to seek FDA approval through the premarket approval (PMA) pathway to market its nsPFA Cardiac Surgical System for the treatment of atrial fibrillation in the US, following which it plans to begin commercialization.

Price: 15.09, Change: +3.04, Percent Change: +25.23